B16 melanomas evade antitumor immunity by the loss of epitope presentation and the acquisition of tumor resistance to granzyme B

B16 melanoma control by anti-PD-L1 requires CD8+T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines

CD8(+) T Cells Directed Against a Peptide Epitope Derived From Peptidoglycan-Associated Lipoprotein of Legionella pneumophila Confer Disease Protection

Regulation of the translation activity of antigen-specific mRNA is responsible for antigen loss and tumor immune escape in a HER2-expressing tumor model

Optimized gemcitabine therapy in combination with E7 peptide immunization elicits tumor cure by preventing Ag-specificc CTL inhibition in animals with large established tumors

Therapeutic Tumor Control of HER2 DNA Vaccines Is Achieved by an Alteration of Tumor Cells and Tumor Microenvironment by Gemcitabine and Anti-Gr-1 Ab Treatment in a HER2-Expressing Tumor Model

Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2

MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model

A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells` antigen presentation to Ag-specific CTLs in a colon cancer model

Combined Stimulation of IL-2 and 4-1BB Receptors Augments the Antitumor Activity of E7 DNA Vaccines by Increasing Ag-Specific CTL Responses